Efficacy and tolerability after unusually low doses of dasatinib in chronic myeloid leukemia patients intolerant to standard-dose dasatinib therapy

Clinical Medicine Insights: Oncology

Volumn 4, Issue , 2010, Pages 155-162

  Serpa, Mariana ^a,b   Sanabani, Sabri S ^a,c   Bendit, Israel ^a   Seguro, Fernanda ^a,b   Xavier, Flávia ^a,b   Barroso, Cláudia Bitti ^b   Conchon, Monika ^a   Dorlhiac Llacer, Pedro Enrique ^a  

^a UNIVERSITY OF SÃO PAULO   (Brazil)

^b Agronomic Institute of São Paulo   (Brazil)

^c FEDERAL UNIVERSITY OF SÃO PAULO   (Brazil)

Author keywords

Adverse events; Chronic myeloid leukemia; Dasatinib administration dosage; Treatment outcome

Indexed keywords

BCR ABL PROTEIN; DASATINIB; HYDROXYUREA; IMATINIB;

ADULT; AGED; ANAMNESIS; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CASE REPORT; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; DOSE RESPONSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; EPISTAXIS; FOLLOW UP; HUMAN; LEUKEMIA REMISSION; LEUKOCYTOSIS; LOADING DRUG DOSE; LOW DRUG DOSE; MALE; PANCREATITIS; PHILADELPHIA 1 CHROMOSOME; SPLENOMEGALY; THROMBOCYTE TRANSFUSION; THROMBOCYTOPENIA; TREATMENT DURATION;

EID: 79751507435     PISSN: 11795549     EISSN: 11795549     Source Type: Journal    
DOI: 10.4137/CMO.S6413     Document Type: Article

References (33)

1. Sawyers CL. Chronic myeloid leukemia. N Engl J Med. 1999 Apr 29;340(17):1330-40.
2. Faderl S, Talpaz M, Estrov Z, O'Brien S, Kurzrock R, Kantarjian HM. The biology of chronic myeloid leukemia. N Engl J Med. 1999 Jul 15;341(3):164-72.
3. Rowley JD. Letter: A new consistent chromosomal abnormality in chronic myelogenous leukaemia identified by quinacrine fluorescence and Giemsa staining. Nature. 1973 Jun 1;243(5405):290-3.
4. Heisterkamp N, Stam K, Groffen J, de Klein A, Grosveld G. Structural organization of the bcr gene and its role in the Ph' translocation. Nature. 1985 Jun 27-Jul 3;315(6022):758-61.
5. Lugo TG, Pendergast AM, Muller AJ, Witte ON. Tyrosine kinase activity and transformation potency of bcr-abl oncogene products. Science. 1990 Mar 2;247(4946):1079-82.
6. Sattler M, Griffin JD. Molecular mechanisms of transformation by the BCR-ABL oncogene. Semin Hematol. 2003 Apr;40(2 Suppl 2):4-10.
7. Sillaber C, Mayerhofer M, Agis H, et al. Chronic myeloid leukemia: pathophysiology, diagnostic parameters, and current treatment concepts. Wien Klin Wochenschr. 2003 Aug 14;115(13-14):485-504.
8. Daley GQ, van Etten RA, Baltimore D. Induction of chronic myelogenous leukemia in mice by the P210bcr/abl gene of the Philadelphia chromosome. Science. 1990 Feb 16;247(4944):824-30.
9. O'Brien S, Berman E, Borghaei H, et al. NCCN clinical practice guidelines in oncology: chronic myelogenous leukemia. J Natl Compr Canc Netw. 2009 Oct;7(9):984-1023.
10. Baccarani M, Cortes J, Pane F, et al. Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol. 2009 Dec 10;27(35):6041-51.
11. Deininger M, O'Brien SG, Guilhot F, et al. International randomized study of interferon vs. STI571 (IRIS) 8-year follow up: sustained survival and low risk for progression of events in patients with newly diagnosed chronic lymphocytic leukemia in chronic phase (CML-CP) treated with imatinib. Blood (ASH Annual Meeting Abstracts). 2009;114(462): (abstr 1126).
12. Hochhaus A, Baccarani M, Deininger M, et al. Dasatinib induces durable cytogenetic responses in patients with chronic myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. Leukemia. 2008 Jun;22(6):1200-6.
13. Kantarjian H, Schiffer C, Jones D, Cortes J. Monitoring the response and course of chronic myeloid leukemia in the modern era of BCR-ABL tyrosine kinase inhibitors: practical advice on the use and interpretation of monitoring methods. Blood. 2008 Feb 15;111(4):1774-80.
14. Weisberg E, Manley PW, Breitenstein W. Characterization of AMN107, a selective inhibitor of native and mutant Bcr-Abl. Cancer Cell. 2005 Feb;7(2):129-41.
15. O'Hare T, Walters DK, Stoffregen EP. In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants. Cancer Res. 2005 Jun 1;65(11):4500-5.
16. Shah NP, Tran C, Lee FY, Chen P, Norris D, Sawyers CL. Overriding imatinib resistance with a novel ABL kinase inhibitor. Science. 2004 Jul 16;305(5682):399-401.
17. Tokarski JS, Newitt JA, Chang CY, et al. The structure of Dasatinib (BMS- 354825) bound to activated ABL kinase domain elucidates its inhibitory activity against imatinib-resistant ABL mutants. Cancer Res. 2006 Jun 1;66(11):5790-7.
18. Wong SF. New dosing schedules of dasatinib for CML and adverse event management. J Hematol Oncol. 2009;2:10.
19. Guilhot F, Apperley J, Kim DW, et al. Dasatinib induces significant hematologic and cytogenetic responses in patients with imatinib-resistant or - intolerant chronic myeloid leukemia in accelerated phase. Blood. 2007 May 15;109(10):4143-50.
20. Ottmann O, Dombret H, Martinelli G, et al. Dasatinib induces rapid hematologic and cytogenetic responses in adult patients with Philadelphia chromosome positive acute lymphoblastic leukemia with resistance or intolerance to imatinib: interim results of a phase 2 study. Blood. 2007 Oct 1;110(7):2309-15.
21. Shah NP, Kim DW, Kantarjian H, et al. Potent, transient inhibition of BCRABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 2010 Feb;95(2):232-40.
22. Dombret H, Ottmann O, Goh Y, et al. Dasatinib 140 mg QD vs. 70 mg BID in advanced-phase CML or PhBBALL resistant or intolerant to imatinib: results from a randomized, Phase-III trial (CA180035). Haematologica. 2007;92(Suppl 1):319. (Proceedings Presented at 12th Congress of the European Hematology Association).
23. Squibb BM. SPRYCEL prescribing information (US). Princeton, NJ: Bristol- Myers Squibb. 2010 Apr.
24. Kantarjian H, Shah NP, Hochhaus A, et al. Dasatinib versus imatinib in newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med. 2010 Jun 17;362(24):2260-70.
25. Varma MR, Mathew S, Krishnadas D, Vinayakumar KR. Imatinib-induced pancreatitis. Indian J Pharmacol. 2010 Feb;42(1):50-2.
26. Palandri F, Castagnetti F, Soverini S, et al. Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure. Haematologica. 2009 Dec;94(12):1758-61.
27. Kantarjian HM, Giles F, Gattermann N, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is effective in patients with Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase following imatinib resistance and intolerance. Blood. 2007 Nov 15;110(10):3540-6.
28. Le Coutre P, Ottmann OG, Giles F, et al. Nilotinib (formerly AMN107), a highly selective BCR-ABL tyrosine kinase inhibitor, is active in patients with imatinib-resistant or -intolerant accelerated-phase chronic myelogenous leukemia. Blood. 2008 Feb 15;111(4):1834-9.
29. Hazarika M, Jiang X, Liu Q, et al. Tasigna for chronic and accelerated phase Philadelphia chromosome-positive chronic myelogenous leukemia resistant to or intolerant of imatinib. Clin Cancer Res. 2008 Sep 1;14(17):5325-31.
30. Santos FP, Kantarjian H, Fava C, et al. Clinical impact of dose reductions and interruptions of second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukaemia. Br J Haematol. 2010 Aug;150(3):303-12.
31. Bergeron A, Rea D, Levy V, et al. Lung abnormalities after dasatinib treatment for chronic myeloid leukemia: a case series. Am J Respir Crit Care Med. 2007 Oct 15;176(8):814-8.
32. Breccia M, Cannella L, Stefanizzi C, Carotti A, Santopietro M, Alimena G. Efficacy of dasatinib in a chronic myeloid leukemia patient with disease molecular relapse and chronic GVHD after haploidentical BMT: an immunomodulatory effect? Bone Marrow Transplant. 2009 Sep;44(5):331-2.
33. Yamaguchi M, Munemoto S, Kasada A, Murata R, Ueda M. Successful treatment using low-dose dasatinib for chronic myelogenous leukemia in a patient with megakaryoblastic transformation concomitant with myelofibrosis and an extramedullary tumor. Leuk Res. 2010 Sep;34(9):e237-9.